Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Alivus Life Sciences Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 621 | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 |
| Expenses + | 415 | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 |
| Operating Profit | 206 | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 |
| OPM % | 33% | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% |
| Other Income + | 3 | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 12 | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 |
| Profit before tax | 198 | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 |
| Tax % | 26% | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% |
| Net Profit + | 146 | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 |
| EPS in Rs | 11.95 | 11.05 | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 |
Financials of Alivus Life Sciences Ltd
Annual income statement trend
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 |
| Expenses + | 0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,702 | 1,755 |
| Operating Profit | -0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 797 |
| OPM % | -4% | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 31% |
| Other Income + | 0 | -0 | 11 | 0 | 14 | 28 | 11 | 33 | 35 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 |
| Profit before tax | -0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 |
| Tax % | 4,200% | 14% | 26% | 25% | 26% | 26% | 25% | 26% | 25% |
| Net Profit + | -0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 |
| EPS in Rs | -430.00 | 997.86 | 1,597.37 | 358.74 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% | 13% | 11% |
Financials of Alivus Life Sciences Ltd
Capital structure and asset base
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings + | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other Liabilities + | 1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | 537 | 594 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed Assets + | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1,048 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 273 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other Assets + | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 | 1,881 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
Financials of Alivus Life Sciences Ltd
Operating, investing and financing cash movement
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Cash from Investing Activity + | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Cash from Financing Activity + | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
| Free Cash Flow | -0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO/OP | 4,800% | 14% | 61% | 84% | 119% | 71% | 85% | 81% | 93% |
Financials of Alivus Life Sciences Ltd
Working capital efficiency and return ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory Days | 162 | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 237 |
| Days Payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 127 |
| Cash Conversion Cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 263 |
| Working Capital Days | -2,059 | -186 | -37 | 12 | 149 | 176 | 188 | 201 | 306 |
| ROCE % | 529% | 186% | 97% | 42% | 30% | 28% | 25% | 25% |